Raymond G. Fox

1.1k total citations
24 papers, 480 citations indexed

About

Raymond G. Fox is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Raymond G. Fox has authored 24 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 8 papers in Hepatology and 7 papers in Molecular Biology. Recurrent topics in Raymond G. Fox's work include Hepatitis C virus research (8 papers), Liver Disease Diagnosis and Treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). Raymond G. Fox is often cited by papers focused on Hepatitis C virus research (8 papers), Liver Disease Diagnosis and Treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). Raymond G. Fox collaborates with scholars based in United States, United Kingdom and France. Raymond G. Fox's co-authors include Tannishtha Reya, Claire S. Koechlein, Frederick D. Park, Marcie Kritzik, Nobuyo Maeda, Tomas A. Prolla, Gregory C. Kujoth, Scott T. Magness, Gareth J. Veal and Alasdair Breckenridge and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

Raymond G. Fox

22 papers receiving 467 citations

Peers

Countries citing papers authored by Raymond G. Fox

Since Specialization

Citations

This map shows the geographic impact of Raymond G. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond G. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond G. Fox more than expected).

Fields of papers citing papers by Raymond G. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond G. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond G. Fox. The network helps show where Raymond G. Fox may publish in the future.

Co-authorship network of co-authors of Raymond G. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond G. Fox. A scholar is included among the top collaborators of Raymond G. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond G. Fox. Raymond G. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types 2025 ·Cancer Research Communications ·(unknown), Thomas S. Dexheimer, Nathan P. Coussens, (unknown), Raymond G. Fox, Samantha B. Kemp, Poorva Juneja, Joel Morris, Melinda G. Hollingshead, Naoko Takebe, James H. Doroshow, Beverly A. Teicher	0
2	P11.63.B VALIDATING THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN CLINICAL PRACTICE: A MULTI-CENTER PROSPECTIVE STUDY IN PATIENTS WITH GLIOBLASTOMA 2023 ·Neuro-Oncology ·(unknown), Raymond G. Fox, Marie Allen, Karen A. Roberto, (unknown), (unknown), (unknown), (unknown), (unknown), Ugonma Chukwueke, (unknown), Eunjung Lee, Patrick Y. Wen, James Perry, David A. Reardon, Lakshmi Nayak	0
3	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study 2020 ·Gut ·Sharon Hutchinson, Heather Valerio, Scott McDonald, Alan C. Yeung, Kevin G. Pollock, (unknown), Stephen T. Barclay, John Dillon, Raymond G. Fox, Peter Bramley, Andrew Fraser, N. Kennedy, Rory Gunson, Kate Templeton, Hamish Innes, Allan McLeod, Amanda Weir, Peter Hayes, David Goldberg	19
4	Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study 2017 ·Gastroenterology ·Barbara Haber, Graham R. Foster, Kosh Agarwal, Matthew Cramp, Sulleman Moreea, Stephen T. Barclay, Jane Collier, Ashley Brown, Stephen Ryder, Andrew Ustianowski, Daniel Forton, Raymond G. Fox, (unknown), William Rosenberg, David Mutimer, Jiejun Du, Christopher L. Gilbert, Michael Robertson, Eliav Barr	3
5	Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study 2017 ·Journal of Hepatology ·Graham R. Foster, Kosh Agarwal, (unknown), Sulleman Moreea, Stephen T. Barclay, Jane Collier, Ashley Brown, Stephen Ryder, Andrew Ustianowski, Daniel Forton, Raymond G. Fox, Fredric D. Gordon, William Rosenberg, (unknown), Jiejun Du, Colin Gilbert, Michael Robertson, Emily Barr, (unknown)	4
6	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials 2016 ·Clinical Infectious Diseases ·Jason Grebely, Gregory J. Dore, Stefan Zeuzem, Richard Aspinall, Raymond G. Fox, Lingling Han, John McNally, Anu Osinusi, Diana M. Brainard, G. Mani Subramanian, (unknown), Graham R. Foster, Alessandra Mangia, Mark Sulkowski, Jordan J. Feld	71
7	High-resolution imaging and computational analysis of haematopoietic cell dynamics in vivo 2016 ·Nature Communications ·Claire S. Koechlein, Jeffrey Harris, Timothy K. Lee, (unknown), Raymond G. Fox, Bryan Zimdahl, Takahiro Ito, (unknown), Seung‐Hye Jung, John P. Chute, (unknown), Markus W. Covert, Tannishtha Reya	22
8	Efficacy of Sofosbuvir/Ledipasvir in Treating Genotype 1 and 4 Hepatitis C for 8/12 Weeks: Results from a Difficult to Treat Cohort 2016 ·Journal of Hepatology ·(unknown), Emma C. Thomson, Shalini Datta, Raymond G. Fox, (unknown), Mathis Heydtmann, Fiona Marra, Stephen T. Barclay	1
9	The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy 2015 ·European Journal of Gastroenterology & Hepatology ·Huan Wang, Hamish Innes, Sharon Hutchinson, David Goldberg, Samuel H. Allen, Stephen T. Barclay, Peter Bramley, Raymond G. Fox, Andrew Fraser, Peter Hayes, N. Kennedy, Peter R. Mills, John Dillon	2
10	Musashi Signaling in Stem Cells and Cancer 2015 ·Annual Review of Cell and Developmental Biology ·Raymond G. Fox, Frederick D. Park, Claire S. Koechlein, Marcie Kritzik, Tannishtha Reya	80
11	OC-115 The use of sofosbuvir based regimens amongst treatment naive and experienced patients with advanced fibrosis/cirrhosis: real world results from a difficult to treat cohort 2015 ·Gut ·David E.R. Sutherland, Ewan Forrest, Mathis Heydtmann, (unknown), (unknown), (unknown), Adrian J. Stanley, Raymond G. Fox, Stephen T. Barclay	1
12	First confirmed case of Crimean-Congo haemorrhagic fever in the UK 2013 ·The Lancet ·David Barr, Celia Aitken, David Bell, Colin Brown, Ian Cropley, (unknown), Susan Hopkins, Michael Jacobs, Benjamin Jeffs, Alisdair MacConnachie, (unknown), Edward Nicol, Raymond G. Fox	16
13	Missed opportunities for HIV diagnosis: a three-year audit in the West of Scotland 2013 ·Scottish Medical Journal ·(unknown), (unknown), Rak Nandwani, (unknown), (unknown), Raymond G. Fox, Edgar J.G. Peters, (unknown), Andrew Winter	11
14	Calcium Dependent CAMTA1 in Adult Stem Cell Commitment to a Myocardial Lineage 2012 ·PLoS ONE ·Barbara J. Muller-Borer, (unknown), (unknown), (unknown), Raymond G. Fox, Nenad Bursac, Sylvia Hiller, (unknown), Neal Shepherd, Jian‐Ping Jin, Mary Redmond Hutson, Page A.W. Anderson, Margaret L. Kirby, Nadia N. Malouf	12
15	Improvement is needed in the documentation and HIV testing of children of HIV-positive women 2012 ·International Journal of STD & AIDS ·(unknown), (unknown), Andrew Winter, Rak Nandwani, Raymond G. Fox, (unknown)	1
16	Mitochondrial DNA polymerase editing mutation, Polg ^D257A , reduces the diabetic phenotype of Akita male mice by suppressing appetite 2011 ·Proceedings of the National Academy of Sciences ·Raymond G. Fox, Hyung‐Suk Kim, Robert L. Reddick, Gregory C. Kujoth, Tomas A. Prolla, Shuichi Tsutsumi, Youichiro Wada, Oliver Smithies, Nobuyo Maeda	12
17	Therapeutic benefits in thalassemic mice transplanted with long-term−cultured bone marrow cells 2010 ·Experimental Hematology ·Seigo Hatada, William G. Walton, (unknown), (unknown), Raymond G. Fox, Naiyou Liu, Michael Lill, (unknown), Suzanne L. Kirby, Oliver Smithies	1
18	The impact of highly active antiretroviral combination therapy in HIV infected patients in Glasgow. 2000 ·PubMed ·Raymond G. Fox, (unknown)	2
19	Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers 1994 ·AIDS ·Michael Barry, Martin K. Wild, Gareth J. Veal, David Back, Alasdair Breckenridge, Raymond G. Fox, Nicholas J. Beeching, (unknown), Peter Carey, (unknown)	58
20	The effect of parenteral lipid emulsion-induced hyperlipidemia on prostaglandin E1 modulation of platelet function. 1993 ·PubMed ·(unknown), (unknown), Raymond G. Fox, (unknown), (unknown), E. Jonas	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact